Thermo Fisher Predicts Strong H2 Sales of New Mass Specs as Q2 Revenues Rise 12 Percent
July 29, 2011
Thermo Fisher Predicts Strong H2 Sales of New Mass Specs as Q2 Revenues Rise 12 Percent
During an investor call discussing the company's second-quarter results, CEO Marc Casper said that the new Velos Pro, Orbitrap Elite, and Q-Exactive mass spectrometers have generated "the largest number of demo requests that we can remember for any products we have launched."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thermo Fisher 'Going Directly After' $250M Q-TOF Market with Release of New Q Exactive Mass Spec
June 10, 2011 / ProteoMonitor - Thermo Fisher's New Orbitrap Elite Poses Challenge to FT-ICR's Dominance in Top-Down Proteomics
July 1, 2011 / ProteoMonitor - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor - U of L Proteomics Core Wins $375K from VA to Add Mass Spec; Eyeing Thermo's New Orbitrap Elite
June 10, 2011 / ProteoMonitor - Thermo Fisher Adds to Specialty-Dx Business with $3.5B Phadia Buy
May 20, 2011 / ProteoMonitor